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Background: During cerebral inflammation uracil nucleotides leak to the extracellular medium and activate glial
pyrimidine receptors contributing to the development of a reactive phenotype. Chronically activated microglia
acquire an anti-inflammatory phenotype that favors neuronal differentiation, but the impact of these microglia on
astrogliosis is unknown. We investigated the contribution of pyrimidine receptors to microglia-astrocyte signaling in
a chronic model of inflammation and its impact on astrogliosis.
Methods: Co-cultures of astrocytes and microglia were chronically treated with lipopolysaccharide (LPS) and
incubated with uracil nucleotides for 48 h. The effect of nucleotides was evaluated in methyl-[3H]-thymidine
incorporation. Western blot and immunofluorescence was performed to detect the expression of P2Y6
receptors and the inducible form of nitric oxide synthase (iNOS). Nitric oxide (NO) release was quantified
through Griess reaction. Cell death was also investigated by the LDH assay and by the TUNEL assay or
Hoechst 33258 staining.
Results: UTP, UDP (0.001 to 1 mM) or PSB 0474 (0.01 to 10 μM) inhibited cell proliferation up to 43 ± 2%
(n = 10, P <0.05), an effect prevented by the selective P2Y6 receptor antagonist MRS 2578 (1 μM). UTP was
rapidly metabolized into UDP, which had a longer half-life. The inhibitory effect of UDP (1 mM) was abolished
by phospholipase C (PLC), protein kinase C (PKC) and nitric oxide synthase (NOS) inhibitors. Both UDP (1 mM)
and PSB 0474 (10 μM) increased NO release up to 199 ± 20% (n = 4, P <0.05), an effect dependent on P2Y6
receptors-PLC-PKC pathway activation, indicating that this pathway mediates NO release. Western blot and
immunocytochemistry analysis indicated that P2Y6 receptors were expressed in the cultures being mainly
localized in microglia. Moreover, the expression of iNOS was mainly observed in microglia and was upregulated by
UDP (1 mM) or PSB 0474 (10 μM). UDP-mediated NO release induced apoptosis in astrocytes, but not in microglia.
Conclusions: In LPS treated co-cultures of astrocytes and microglia, UTP is rapidly converted into UDP, which activates
P2Y6 receptors inducing the release of NO by microglia that causes astrocyte apoptosis, thus controlling their rate of
proliferation and preventing an excessive astrogliosis.
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Chronic inflammation is characteristic of several brain
disorders leading to loss of cognitive function. In the
central nervous system (CNS), the inflammatory re-
sponse is mediated by glial cells that acquire reactive
phenotypes to participate in neuronal repair mechanisms
[1,2]. In particular, astrocytes respond with a complex
reaction named astrogliosis that includes several mor-
phological and functional changes, such as cell hyper-
trophy, glial fibrillary acidic protein (GFAP) and nestin
up-regulation [3], and cell proliferation [4]. These pro-
gressive changes are time and context dependent, being
regulated by inflammatory mediators produced in the le-
sion site [5]. Activated microglia are the main source of
these inflammatory mediators, assuming an important
role in the modulation of astrogliosis progression during
the course of the inflammatory response [6,7]. These
mediators may be pro-inflammatory, such as IL-1β,
TNF-α and nitric oxide (NO), or anti-inflammatory,
such as IL-10, IL-4, TGF-β, according to the microglia
phenotype, which is highly dependent on the pathological
context [2,8]. Lipopolysaccharide (LPS) is an agonist of
toll-like receptors-4 (TLR4), inducing a pro-inflammatory
phenotype in microglia. However, chronic activation of
TLR4 receptors has been shown to promote microglia
polarization toward an anti-inflammatory phenotype
[9,10], but its impact in the inflammatory response and in
the modulation of astrogliosis remains to be established.
In fact, different extents of astrogliosis and microgliosis
have different impacts in neuronal regeneration [1,2]. In
the extreme end of the astrogliosis spectrum, proliferat-
ing astrocytes may interact with fibroblasts and other
glial cells to form a glial scar, creating an environment
that prevents axon regeneration [11], leading to the idea
that inhibition or control of this response would be
beneficial to neuronal survival after injury. Therefore,
the mediators produced by chronically activated micro-
glia may have an important role to prevent excessive
astrogliosis and promote neuronal regeneration and
sprouting.
In a context of chronic brain inflammation, both aden-
ine and uracil nucleotides attain high concentrations in
the extracellular medium (in the mM range) due to cell
damage or death, and activate P2 receptors in both types
of glial cells, contributing to astrogliosis [12] and reinfor-
cing the release of inflammatory messengers produced by
microglia [13]. Particularly, the uracil nucleotides may ac-
tivate pyrimidine receptors, such as the P2Y2,4,6 and P2Y14
receptor subtypes [14] that participate in the inflammatory
response [15]. P2Y6 receptors contribute to the clearance
of necrotic cell debris by stimulating microglia phagocyt-
osis of dying neurons [16], whereas the P2Y2 receptors
mediate astrocyte migration [17], but the effect of uracil
nucleotides in the modulation of astroglial proliferationand their role in the control of glial scar formation is
largely unknown.
To investigate the role of pyrimidine receptors in
microglia-astrocyte signaling and its impact in the con-
trol of astrogliosis, it was used a cell culture model that
could represent a state of chronic brain inflammation,
which consisted of co-cultures of astrocytes and mic-
roglia submitted to a long-term treatment with LPS
(0.1 μg/ml). The cultures obtained were used to investi-
gate: i) the effect of uracil nucleotides in cell prolifera-
tion, ii) the influence of ectonucleotidases on uracil
nucleotides metabolism and consequent impact in cell
proliferation, iii) the signaling pathways and the mecha-
nisms activated by the pyrimidine receptors involved in
the control of cell proliferation, and iv) the contribution




The antibodies used and the respective information are
listed in Table 1. The following drugs and reagents were
used: L-arginine (L-ARG), lipopolysaccharide from Sal-
monella thyphimurium (LPS), N-nitro-L-arginine methyl
ester hydrochloride (L-NAME), pertussis toxin (PTX),
bisindolylmaleimide XI hydrochloride (RO 32-0432),
penicillin, streptomycin, uracil, uridine, uridine-5’-mono-
phosphate disodium (UMP), uridine-5’-diphosphate so-
dium (UDP), uridine 5'-triphosphate trisodium (UTP),
uridine 5'-diphosphoglucose disodium (UDP-glucose),
1-[6-[((17β)-3-methoxyestra-1,3,5[10]-trien-17-yl)amino]
hexyl]-2,5-pyrrolidinedione (U 73343), 1-[6-[((17β)-3-me-
thoxyestra-1,3,5[10]-trien-17-yl)amino]hexyl]-1H-pyrrole-2,
5dione (U 73122), 2'-(4-hydroxyphenyl)-5-(4-methyl-1-
piperazinyl)-2,5'-bi-1H-benzimidazole trihydrochloride
hydrate (Hoechst 33258), Ribonuclease A (RNAse) and
propidium iodide (PI) from Sigma-Aldrich (Sintra, Portugal);
N,N''-1,4 butanediylbis[N'-(3-isothiocyanatophenyl)thiourea]
(MRS 2578) and 3-(2-oxo-2-phenylethyl)uridine-5'-diphos-
phate disodium (PSB 0474) from Tocris (Bristol, UK);
methyl-[3H]thymidine (specific activity 80 to 86 Ci/mmol)
and enhanced chemiluminescence (ECL) western blotting
system from Amersham Biosciences (Lisbon, Portugal).
Stock solutions of drugs were prepared with dimethyl sulf-
oxide or distilled water and kept at -20°C. Solutions of
drugs were prepared from stock solutions diluted in cul-
ture medium immediately before use.
Cell cultures
Animal handling and experiments were in accordance
with the guidelines prepared by Committee on Care and
Use of Laboratory Animal Resources (National Research
Council, USA), followed the Directive 2010/63/EU of the
European Parliament and the Council of the European
Table 1 Primary and secondary antibodies used in immunocytochemistry and western blotting
Primary antibodies
Antigen Code Host Dilution Supplier
GFAP G9269 Rabbit 1:600 (IF) Sigma
GFAP G6171 Mouse 1:600 (IF) Sigma
CD11b sc-53086 Mouse 1:50 (IF) Santa Cruz Biotechnology, Inc
P2Y6 APR-011 Rabbit 1:200 (IF) Alomone
1:300 (WB)
iNOS AB5382 Rabbit 1:5 000 (IF) Chemicon
Actin sc-1615-R Rabbit 1:200 (WB) Santa Cruz Biotechnology, Inc
Secondary antibodies
Antigen Code Host Dilution Supplier
TRITC anti-rabbit T6778 Goat 1:400 (IF; GFAP, P2Y6) Sigma
1:2 000 (IF; iNOS)
Alexa Fluor 488 anti-mouse A-11034 Goat 1:400 (IF) Mol. Probes
anti-rabbit conjugated to horseradish peroxidase sc-2004 Goat 1:10 000 (WB) Santa Cruz Biotechnology, Inc
IF, immunofluorescence; WB, western blot analysis.
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the Faculty of Pharmacy from the University of Porto.
Primary co-cultures of astrocytes and microglia were
prepared from newborn (P0-P2) Wistar rats (Charles
River, Barcelona, Spain) as previously described [18] with
minor modifications. Cell cultures were treated with
0.1 μg/ml LPS and were incubated at 37°C in a humidi-
fied atmosphere of 95% air, 5% CO2. The medium con-
taining 0.1 μg/ml LPS was replaced one day after cell
cultures preparation, and subsequently, twice a week,
with LPS remaining in the cultures from the first day
in vitro (DIV1) until the end of the experiments. Cul-
tures were synchronized to a quiescent phase of the cell
cycle, by shifting fetal bovine serum concentration in the
medium from 10% to 0.1% for 48 h, and then used in ex-
periments at DIV30.Immunocytochemistry
Cultures were fixed and permeabilized as described in
previous studies [19]. For double immunofluorescence,
cultures were incubated with the primary antibodies
(Table 1) overnight at 4°C. Visualization of GFAP, CD11b,
and P2Y6 receptors and iNOS positive cells was accom-
plished upon 1 h incubation, at room temperature, with
the secondary antibodies (Table 1). In negative controls,
the primary antibody was omitted. Cell nuclei were la-
beled with Hoechst 33258 (5 μg/ml) for 30 min at room
temperature. To evaluate the percentage of microglia in
the cultures, approximately 200 cells per culture were
counted, and the number of CD11b positive cells was
expressed as percentage of the total number of cells
counted.DNA synthesis
Cultures grown in 24-well plates were incubated with
uracil nucleotides or solvent for 48 h, and methyl-[3H]-
thymidine was added in the last 24 h, at a concentration
of 1 μCi/ml. Antagonists or enzymatic inhibitors were
added to the medium 1 h before uracil nucleotides. In
experiments performed in the presence of PTX, the drug
was added to the culture medium 24 h before the uracil
nucleotides. At the end of the 48-h period of incubation,
the protein content and methyl-[3H]-thymidine incorp-
oration were evaluated as previously described [20].
Metabolism of nucleotides
The metabolism of nucleotides was evaluated as previ-
ously described [20]. Briefly, cultures were incubated
with uracil nucleotides, all at 0.1 mM, and samples were
collected at 0, 1, 3, 8, 24 and 48 h. For evaluation of
UTP half-life, additional samples were collected at 0, 5,
10, 15, 30, 60 min. The uracil nucleotides or their me-
tabolites were separated and quantified by ion-pair-
reverse-phase high-performance liquid chromatography
(HPLC) with UV detection set at 254 nm [21]. Standards
were analyzed in the same conditions and the retention
time identified was (min): uracil (0.95), uridine (1.32),
UMP (2.15), UDP (4.40) and UTP (6.40). The concentra-
tion of nucleotides and metabolites was calculated by
peak area integration, followed by interpolation in cali-
bration curves obtained with standards.
Western blot analysis
The expression of P2Y6 receptors was evaluated as pre-
viously described [22]. Membranes were probed for 2 h
at room temperature with appropriately diluted primary
Figure 1 Immunofluorescent micrograph representative of
co-cultures treated with lipopolysaccharide (LPS) (0.1 μg/ml).
Astrocytes were labeled with rabbit anti-GFAP (TRICT, red) and
microglia with mouse anti-CD11b (Alexa Fluor 488, green). The
percentage of microglia in cultures was 4.36 ± 0.42% (n = 5). Scale
bar: 50 μm.
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followed by the secondary antibody goat anti-rabbit IgG
conjugated to horseradish peroxidase (Table 1). The
immunocomplexes were detected by ECL.
Nitric oxide assay
Cultures were incubated with uracil nucleotides or solv-
ent for 48 h. The P2Y6 antagonist MRS 2578 or other
enzyme inhibitors, when tested, were added 1 h before
the uracil nucleotides. At the end of the 48-h period of
incubation, the nitric oxide released into the culture
medium was assessed by measuring the accumulation of
nitrates plus nitrites according to the instructions of a
Nitrate/Nitrite Colorimetric Assay kit (Cayman, France).
The content of nitrates plus nitrites present in the sup-
ernatants was expressed as percentage of respective
control.
Cell cycle
The ability of uracil nucleotides to arrest glial cells in a
specific cell cycle stage was evaluated in cultures treated
with uracil nucleotides or solvent for 48 h. Cells were
harvested by trypsinization, rinsed with ice-cold PBS and
fixed in ice-cold 70% ethanol for 15 min at -20°C. Cells
were rinsed again with PBS and incubated with 0.2 mg/
ml RNAse A at 37°C for 15 min and further with
0.5 mg/ml propidium iodide for at least 30 min in the
dark at room temperature. The percentage of cells in
each phase of the cell cycle was determined by a flow cy-
tometric analysis using the FACSCalibur flow cytometer
from BD Biosciences (Enzifarma, Porto, Portugal) and
the CellQuest software from BD Biosciences (Enzifarma,
Porto, Portugal). Cell cycle phases were identified and
quantified using ModFit LT software (Verity Software
House Inc., Topsham, USA).
Cell death assays
Necrotic cell death was assessed by measuring the lac-
tate dehydrogenase (LDH) release with an enzymatic
assay according to the manufacturer’s instructions
(Sigma-Aldrich, Sintra, Portugal). Cultures were incu-
bated with uracil nucleotides or solvent for 48 h. LDH
activity was determined in the culture supernatants and
respective extracts. The amount of LDH released into
the culture medium was expressed as the percentage of
total LDH.
Apoptotic cell death was evaluated either by the indirect
terminal transferase-mediated dUTP-digoxigenin nick
end-labeling (TUNEL) to detect DNA fragmentation
using an ApopTag peroxidase detection kit (Millipore,
Madrid, Spain), or by the analysis of nuclear morph-
ology with Hoechst 33258 staining (described above).
Cultures were treated with uracil nucleotides or solvent
for 48 h and, when present, L-NAME was added 1 hbefore nucleotides. The number of TUNEL positive
cells was evaluated as previously described [20]. The
number of apoptotic cells, observed with Hoechst
33258 staining, was evaluated by analyzing eight high-
power fields (×400) in each culture, and the number of
cells showing shrunken nuclei with a bright fluores-
cence appearance was expressed as percentage of total
cell number counted.Statistical analysis
Data are expressed as means ± standard errors of the
mean (SEM) from n number of experiments. Statistical
analysis was carried out using the unpaired Student’s t-
test or ANOVA followed by Dunnett’s multiple compari-
son test. Significant differences were indicated by P
values lower than 0.05.Results
Characterization of the co-cultures
The primary cortical brain cultures treated with lipo-
polysaccharide (LPS; 0.1 μg/ml) for 30 days in vitro, con-
sisted of monolayers of astrocytes exhibiting a flattened,
polygonal morphology and containing 4.36 ± 0.42% (n = 5)
of microglia spread over the top of the astrocyte mono-
layer (Figure 1). The co-cultures obtained were named
LPS cultures where microglial cells exhibited an amoeboid
phenotype with retracted or short thick processes, sug-
gestive of their activation [23], as expected for in vitro LPS
treated microglia. In support of the potential of LPS to ac-
tivate microglia and to prevent their proliferation, it was
observed that in co-cultures grown without any treatment,
the percentage of microglia was higher, approximately
8.0%, and presented longer processes [22].
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fect of uracil nucleotides in cell proliferation, as well as
the contribution of activated microglia to this response.
Effects of uracil nucleotides in cell proliferation
LPS cultures were incubated with several uracil nucleo-
tides to evaluate their influence in cell proliferation.
UTP that activates the P2Y2,4 subtypes, UDP and its
analogue PSB 0474, both selective for the P2Y6 receptors
and UDP-glucose that is selective for the P2Y14 recep-
tors [14] were tested in a wide range of concentrations.
Except for UDP-glucose, the uracil nucleotides UTP,
UDP and PSB 0474 caused a concentration-dependent
inhibition of cell proliferation (Figure 2).
Extracellular metabolism of uracil nucleotides
UTP metabolism was very fast, with a half-life of 10.3 ±
0.5 min (n = 5), and the main metabolite formed during
the first hour was UDP, which remained in the medium
up to 8 h (Figure 3A). When tested from the beginning,
UDP metabolism was much slower compared to that of
UTP (Figure 3B); its half-life was 77.3 ± 2.3 min (n = 4;
P <0.05). The PSB 0474 half-life could not be evaluated
because the highest concentration tested that caused anFigure 2 Effects of uracil nucleotides in cell proliferation.
Lipopolysaccharide (LPS) cultures were incubated with nucleotides
for 48 h and in the last 24 h methyl-[3H]-thymidine was added to
the medium at a concentration of 1 μCi/ml. Effects in cell proliferation
were estimated by methyl-[3H]-thymidine incorporation and expressed
in percentage of control. Values are means ± SEM from five to ten
experiments. *P <0.05, significant differences from control.inhibition of cell proliferation was still below the detec-
tion limit of the method used to study the metabolism
of these compounds.
Expression and pharmacological characterization of the
P2Y receptor subtype involved in the inhibition of cell
proliferation induced by uracil nucleotides
The inhibitory effect of both PSB 0474 (1 μM) and UDP
(1 mM) in cell proliferation was abolished by the selective
P2Y6 receptor antagonist MRS 2578 (1 μM; Figure 4A).
The inhibitory effect of UTP (0.1 mM) was also abolished
by MRS 2578 (not shown), suggesting that this effect de-
pends on its conversion into UDP and activation of P2Y6
receptors. Uncoupling Gi/o proteins from receptors with
pertussis toxin (PTX, 0.1 μg/ml) did not change the effect
of UDP (1 mM), which was attenuated by the phospholip-
ase C (PLC) inhibitor U 73122 (1 μM), but not by its in-
active analog U 73343 (1 μM), and by the protein kinase C
(PKC) inhibitor RO 32-0432 (1 μM; Figure 4A), confirm-
ing the coupling of P2Y6 receptors to the Gq-PLC-PKC
pathway.
P2Y6 receptor expression in LPS cultures comprised
four bands, two of 25 kDa, one of 36 kDa and another
of 86 kDa, which were all absent in the presence of the
P2Y6 receptor neutralizing peptide (np, Figure 4B). Ana-
lysis of the cellular localization of P2Y6 receptors by im-
munocytochemistry revealed a preferential co-localization
with microglia (Figure 5), suggesting that uracil nucleo-
tides may inhibit cell proliferation via microglial cells.
P2Y6 receptor-mediated nitric oxide production
LPS increases iNOS expression and NO production by
microglia [24,25], but this effect is attenuated during
chronic LPS stimulation [9,10]. Since NO may inhibit
astroglial proliferation [26] it was investigated whether
P2Y6 receptor activation by uracil nucleotides modulated
NO release in chronic LPS stimulated microglia. UDP
(1 mM) and PSB 0474 (10 μM) increased NO release in
the culture medium (Figure 6), an effect abolished by
the selective antagonist of the P2Y6 receptors MRS 2578
(1 μM) and by the PLC inhibitor U 73122 (1 μM), or by
the PKC inhibitor RO 32-0432 (1 μM; Figure 6). Add-
itionally, the inhibitory effect of UDP in cell proliferation
(1 mM; 44 ± 2, n = 25) was abolished by the NOS inhibi-
tor L-NAME (0.1 mM; 7 ± 3, n = 8, P <0.05), and this ef-
fect was reversed in the presence of L-arginine (3 mM;
28 ± 6, n = 6; P <0.05).
In order to identify the cellular source of NO released
upon P2Y6 receptor activation, the expression of iNOS
was immunolocalized either with microglia or astrocytes
in LPS cultures. No iNOS expression was detected in as-
trocytes, in control conditions and after treatment with
the uracil nucleotides (Figure 7), whereas in microglia
iNOS expression was residual in control conditions but
Figure 3 Metabolism of uracil nucleotides in lipopolysaccharide (LPS) cultures. Cells were incubated with 0.1 mM of (A) UTP or (B) UDP
and samples were collected at 0, 1, 3, 8, 24 and 48 h. Uracil nucleotides and their metabolites were quantified by HPLC-UV. Values are means ±
SEM from four experiments.
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PSB 0474 (10 μM) or UDP (1 mM; Figure 7).
P2Y6 receptor-mediated inhibition of cell proliferation:
mechanisms involved
In these experimental conditions, microglial cells are re-
sponsible for NO production mediated by P2Y6 receptors.
To clarify the mechanisms behind uracil nucleotidesFigure 4 Pyrimidine receptors and signaling pathway involved in the
(A) Lipopolysaccharide (LPS) cultures were incubated with the nucleotides
the medium at a concentration of 1 μCi/ml. The P2Y6 antagonist MRS 2578
nucleotides, except PTX, which was added to the medium 24 h before. Effe
incorporation and expressed as percentage of change from the respective
*P <0.05, significant differences from respective control; +P <0.05, significan
blots showing the expression of P2Y6 receptors obtained from whole cell l
specifically reacted with the anti-P2Y6 antibody. These bands were absent iinhibition of cell proliferation, their effect on cell cycle
progression and cell death was investigated.
Uracil nucleotides had no effect in cell cycle progres-
sion of glial cells. The percentage of cells in G0/G1, S or
G2/M phase of the cell cycle was similar in control cul-
tures (75.4 ± 1.8, 17.6 ± 3.2, 7.1 ± 1.5, respectively, n = 3)
and those treated with UDP (1 mM; 76.4 ± 1.8, 13.6 ±
2.8, 10.0 ± 1.5, respectively, n = 3), therefore excludinginhibition of cell proliferation mediated by uracil nucleotides.
for 48 h and in the last 24 h methyl-[3H]-thymidine was added to
and enzyme inhibitors were added to the medium 1 h before the
cts in cell proliferation were estimated by methyl-[3H]-thymidine
control. Values are means ± SEM from eight to twenty experiments.
t differences from the agonist alone. (B) Representative western
ysates. Two bands of 25 kDa, one of 36 kDa and another of 86 kDa,
n the presence of the respective neutralizing peptide (np).
Figure 5 Cellular distribution and localization of P2Y6 receptors in lipopolysaccharide (LPS) cultures. Microglia were labeled with mouse
anti-CD11b (Alexa Fluor 488, green), P2Y6 receptors were labeled with rabbit anti-P2Y6 (TRICT, red) and nuclei were labeled with Hoechst 33258
(blue). The orange spots represent the expression of P2Y6 receptors that are coincident with microglia, but not in astrocytes (blue nuclei that do
not label with CD11b and P2Y6 receptor antibodies). Scale bar: 20 μm.
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ition of cell proliferation.
Another possibility was that inhibition of cell prolifera-
tion mediated by uracil nucleotides could result from an
increase in cell death. UDP (1 mM) and PSB 0474
(10 μM) caused no change in LDH release, which ex-
cluded cell death by necrosis (Figure 8A). However, both
UDP (1 mM) and PSB 0474 (10 μM) induced cell death
by apoptosis assessed by the TUNEL assay (Figure 8A).
Cultures treated with UDP (1 mM) showed an increase
in the number of shrunken nuclei with a bright fluores-
cence appearance obtained by Hoechst 33258 staining
(Figure 8B). The percentage of apoptotic nuclei in control
cultures was 6.75 ± 0.65% (n = 8) and increased to 16.02 ±
0.75% (n = 8, P <0.05) in cultures treated with UDP
(1 mM). This increase in the number of apoptotic cells
was attenuated to 11.83 ± 0.61% (n = 8, P <0.05) when
UDP was tested in the presence of L-NAME (0.1 mM).
Additionally, the apoptotic nuclei co-localized with astro-
cytes but not with microglia (Figure 8B).
Discussion
The CNS, with the contribution of glial cells (both astro-
cytes and microglia), has been shown to be able to
mount an innate immune reaction in response to danger
signals, such as endogenous nucleotides released upon
cerebral injury or exogenous pathogens, systemic bac-
teria or virus [27]. It is now well recognized that micro-
glia functional plasticity is strictly stimuli-dependent
[2,8]; however, it is not known how microglia coordinatethe inflammatory response and the progress of astroglio-
sis in a paradigm of chronic glia activation, characteristic
of several inflammatory pathologies. Exposure of CNS to
endotoxins, such as LPS, is a useful approach to activate
immunity, in particular microglial cells [28]. Therefore,
such immunological challenge was used in an in vitro
model where microglia and astrocytes were present and
could cooperate to reproduce some of the conditions
that might be observed during chronic brain inflamma-
tion. It consisted of co-cultures of astrocytes containing
4 to 5% microglia chronically stimulated with 0.1 μg/ml
LPS for 30 days.
In previous studies, we have shown that in co-cultures
of astrocytes and microglia containing a higher percent-
age of microglia, but without LPS treatment, UTP
caused an inhibition of cell proliferation that could be
correlated with a higher expression of P2Y6 receptors in
microglia. In contrast, in highly enriched astroglial cul-
tures, either treated or not with LPS, uracil nucleotides
had no effect in cell proliferation [22], suggesting a fun-
damental role of microglial cells to the P2Y6 receptor-
mediated inhibitory effect. In LPS cultures, UTP also
inhibited cell proliferation and this effect was extensive
to UDP and to the selective agonist of the P2Y6 recep-
tors PSB 0474 [29], but not to the selective agonist of
P2Y14 receptors UDP-glucose [30]. The inhibitory effect
of uracil nucleotides was mediated by P2Y6 receptors,
since it was abolished by MRS 2578, the selective antag-
onist of this receptor subtype [31]. Although UTP has
some affinity for P2Y6 receptors [32], its inhibitory effect
Figure 6 Nitric oxide synthesis mediated by uracil nucleotides in lipopolysaccharide (LPS) cultures. Cells were incubated with UDP or PSB
0474 for 48 h. The P2Y6 antagonist MRS 2578 and enzyme inhibitors were added to the medium 1 h before the nucleotides. The concentration
of nitrites plus nitrates was evaluated in the culture supernatants and was expressed as percentage of change from the respective control. Values
are means ± SEM from four experiments. *P <0.05, significant differences from the respective control; +P <0.05, significant differences from the
agonist alone.
Quintas et al. Journal of Neuroinflammation 2014, 11:141 Page 8 of 12
http://www.jneuroinflammation.com/content/11/1/141was mainly dependent on its metabolism and formation
of UDP, since UTP had a very short half-life, being rapidly
converted into UDP, which remained in the culture
medium for about 8 h. This conclusion is further sup-
ported by the observation that an inhibitory effect of UTP
and of other uracil nucleotides was already observed
within 8 h of incubation (not shown) before a significant
accumulation of the other metabolites, such as uridine or
uracil could be detected in the culture medium.
UDP half-life was much longer than that of UTP,
which may be explained by the NTPDases expressed in
these cultures. Microglia express mainly NTPDase1,
which hydrolyses UTP faster than UDP [33], and astro-
cytes, the main cell type present in these cultures, ex-
press high levels of NTPDase2 [34]. This enzyme seems
to be upregulated upon LPS stimulation [35] and prefer-
entially hydrolyzes UTP compared to UDP [36]. Thus,
the predominance of NTPDase2 activity in these cul-
tures favors UDP accumulation and a preferential activa-
tion of P2Y6 receptors.P2Y6 receptors were coupled to the Gq-PLC-PKC path-
way [14]; however activation of this pathway in astrocytes
has been shown to mediate cell proliferation [20], suggest-
ing a microglial localization. Therefore, the mechanisms
involved in the inhibitory effect mediated by P2Y6 recep-
tors were further investigated by looking to the cellular
localization of these receptors. Expression of P2Y6 recep-
tors in LPS cultures revealed a multiple band pattern, as
previously described and discussed [22]. Only three of the
four bands were lost after adsorption with the neutralizing
peptide, suggesting this antibody is detecting some other
antigen [37]. The cellular localization of P2Y6 receptors
was analyzed by immunocytochemistry, which revealed
that this P2Y6 antibody reacts mainly with microglial anti-
gens. This observation is also in agreement with previous
studies showing an up-regulation of P2Y6 receptor expres-
sion in LPS-activated microglia [16,38]. Although there
are no specific P2Y6 antibodies available [37], results ob-
tained by western blot and immunocytochemistry analysis,
together with pharmacological data and the fact that UDP
Figure 7 Cellular localization of inducible nitric oxide synthase (iNOS) in lipopolysaccharide (LPS) cultures. Cells were incubated with
UDP or PSB 0474 for 48 h. Microglia were labeled with mouse anti-CD11b (Alexa Fluor 488, green), astrocytes with mouse anti-GFAP (Alexa Fluor
488, green) and iNOS with rabbit anti-iNOS (TRITC, red). Cell nuclei were labeled with Hoechst 33258 (blue). The orange spots represent the
expression of iNOS in the cells and are coincident with an increased expression of iNOS in microglia, but not in astrocytes, upon stimulation with
the uracil nucleotides. Scale bar = 10 μm.
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support the conclusion that P2Y6 receptors are mainly lo-
calized in microglia.
LPS increases iNOS expression and NO production in
microglia via PKC activation [24,25,39]. However, NO
release by microglia decays upon chronic LPS stimula-
tion [9,10] suggesting a downregulation of this signaling
pathway. In LPS cultures, all the uracil nucleotides that
inhibited cell proliferation also increased the release of
NO, an effect mediated by P2Y6 receptors coupled to
the PLC-PKC pathway. Thus, a crosstalk between LPS
and P2Y6 receptors signaling pathways may ensure add-
itional iNOS expression and NO production when LPS
response is already downregulated. The inhibitory effect
of UDP was also prevented by L-NAME, a NOSinhibitor, confirming the involvement of NO that was
shown to be exclusively produced by microglia iNOS
[25,40]. Our results confirm previous observations, since
only microglia showed iNOS immunoreactivity, which
was upregulated when LPS cultures were treated with
uracil nucleotides, suggesting that microglia are the
main source of NO detected in the culture medium,
either under basal conditions or upon P2Y6 receptor
activation.
NO may potentially damage cells through the forma-
tion of reactive nitrogen species that cause DNA frag-
mentation [41]. This mechanism could be responsible
for the inhibition of cell proliferation induced by uracil
nucleotides, since these compounds increased the num-
ber of cells presenting DNA fragmentation, an indicator
Figure 8 Effects of uracil nucleotides in cell death in lipopolysaccharide (LPS) cultures. (A) Necrotic cell death was evaluated by measuring
the release of lactate dehydrogenase (LDH) and apoptotic cell death was evaluated by the TUNEL assay, after incubation with uracil nucleotides
or solvent for 48 h. LDH activity was measured in the culture medium and in the culture extracts and the fraction released is represented in
percentage of total LDH. The number of apoptotic cells was expressed as percentage of the total number of cells counted. Values are means ±
SEM from four to seven experiments. *P <0.05, significant differences from respective control (solvent). (B) Cellular localization of apoptotic nuclei,
obtained with the Hoechst 33258 staining in LPS cultures. Astrocytes were labeled with rabbit anti-GFAP (TRITC, red), microglia with mouse
anti-CD11b (Alexa Fluor 488, green) and cell nuclei with Hoechst 33258 (blue). LPS cultures were incubated with solvent or UDP for 48 h.
Shrunken nuclei with a bright fluorescence appearance, characteristic of apoptotic nuclei are clearly coincident with astrocytes (white arrows),
but not with microglia. Scale bar = 20 μm.
Figure 9 Schematic representation of the purinergic mechanisms mediating microglia-astrocyte communication in lipopolysaccharide
(LPS) cultures. Uracil nucleotides released during inflammatory response activate microglia P2Y6 receptors coupled to the phospholipase C
(PLC) - protein kinase C (PKC) pathway, which mediates an increase in inducible nitric oxide synthase (iNOS) expression and consequently, in nitric
oxide (NO) release. Diffusible NO mediates astroglial apoptosis.
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mediated apoptosis is preceded by cell cycle arrest [42],
which was not observed in this study. In LPS cultures,
UDP induced cell death without any previous effect in
the cycle of confluent and synchronized cells. P2Y6 re-
ceptor activation and NO release only affected astro-
cytes, but not microglia viability. Shrunken nuclei with a
bright fluorescence appearance, indicating chromatin
condensation characteristic of apoptotic cells, were highly
coincident with astrocytes but did not co-localize with
microglia. Because cell population in the S-phase of the
cell cycle was not changed by UDP, an increase in NO
release seems to result from iNOS upregulation of indi-
vidual pre-existent microglia, excluding the possibility
of microglia proliferation. This result also indicates that
P2Y6 receptors do not mediate microglia proliferation
and therefore, their activation cannot modify the anti-
proliferative profile established by 0.1 μg/ml LPS [43].
Although uracil nucleotides had no effect in highly
enriched astroglial cultures, cell death by apoptosis me-
diated by pyrimidine receptors was already observed in
co-cultures of astrocytes and microglia (without LPS
treatment), but to a smaller extent [22], suggesting that
LPS and/or uracil nucleotides are not able to induce
astrocyte death without the contribution of microglia.
Nevertheless, it seems that in co-cultures of astrocytes
and microglia, LPS potentiates astrocyte apoptosis medi-
ated by uracil nucleotides, since it increases from 6% in
co-cultures without LPS treatment [22] to 15% in LPS
cultures. LPS facilitates P2Y6 receptor-mediated NO re-
lease by microglia, but other cytokines such as IL-1β or
TNF-α [44] may come into play contributing to astro-
glial cell death.
Conclusions
The present study shows that chronically activated
microglia influence the astroglial response to uracil nu-
cleotides favoring astroglial apoptosis as a consequence
of microglial P2Y6 receptor activation that induces NO
release (Figure 9). Therefore, P2Y6 receptor activation
may represent an important mechanism by which
microglia control excessive astrogliosis that may hamper
neuronal regeneration. Nevertheless, it is known that
human cortical astrocytes are diverse and structurally
and functionally more complex than their rodent coun-
terparts [45]; therefore this hypothesis should be further
confirmed within human glial cells.
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